[6-K] Telix Pharmaceuticals Ltd Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Telix Pharmaceuticals Limited submitted a Form 6-K to share with U.S. investors an announcement it filed with the Australian Securities Exchange. The attached announcement, titled “Precision Medicine Portfolio Update: Illuccix China Phase 3 Study, TLX101-CDx and TLX250-CDx FDA Resubmissions,” outlines developments in Telix’s precision medicine portfolio. This report mainly serves to furnish that ASX announcement as Exhibit 99.1 for the U.S. market.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the month of December, 2025

Commission File Number: 001-42128

Telix Pharmaceuticals Limited

(Translation of registrant’s name into English)

55 Flemington Road

North Melbourne, Victoria 3051, Australia

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

1

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

On December 22, 2025 (Melbourne, Australia), Telix Pharmaceuticals Limited filed an announcement with the Australian Securities Exchange titled “Precision Medicine Portfolio Update: Illuccix China Phase 3 Study, TLX101-CDx and TLX250-CDx FDA Resubmissions,” which is attached to this Form 6-K as Exhibit 99.1.

99.1 Press release – December 22, 2025

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Telix Pharmaceuticals Limited
Date: December 22, 2025	By:	/s/ Genevieve Ryan
		Name: Genevieve Ryan
		Title: Company Secretary